Anticoagulant News and Research RSS Feed - Anticoagulant News and Research

Findings raise hope for new oral anticoagulants to treat patients with atrial fibrillation

Findings raise hope for new oral anticoagulants to treat patients with atrial fibrillation

Approximately one in two patients with atrial fibrillation (Afib) do not optimally reduce their risk of stroke or bleeding when treated with the most widely prescribed oral-anticoagulant therapy, according to a study published online in Circulation, the journal of the American Heart Association. [More]
Aspirin prescribed more often for stroke prevention in AF despite of dangerous side effects

Aspirin prescribed more often for stroke prevention in AF despite of dangerous side effects

Aspirin is still overprescribed for stroke prevention in atrial fibrillation (AF) despite the potential for dangerous side effects, according to research published today. [More]
Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted an orphan drug designation to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of delayed graft function in renal transplant patients. [More]

Study shows that anticoagulant medicine appears to protect patients against stroke

​Heart palpitations. Shortness of breath. Tiredness. More and more people can recognise the symptoms of atrial fibrillation, which is one of the most common types of heart disease. [More]

Daiichi Sankyo submits Marketing Authorization Application for edoxaban to EMA

Daiichi Sankyo, Company Limited (hereafter, Daiichi Sankyo) today announced that the Marketing Authorization Application for its investigational, oral, once-daily direct factor Xa-inhibitor edoxaban has been submitted to the European Medicines Agency. [More]

ESC presents results of pilot registry on management and treatment of AF in Europe

Results for a pilot registry on the management and treatment of atrial fibrillation in Europe were presented yesterday by the European Society of Cardiology. AF is the commonest cardiac rhythm disorder and each of us have a one-in-four lifetime risk of developing it. Statistics show that oral anticoagulant use has increased, but new oral anticoagulant use is still low. Authors also concluded that compliance with treatment guidelines for patients with the lowest and higher stroke risk scores remains suboptimal. [More]

Daiichi Sankyo submits LIXIANA supplemental NDA for review in Japan

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a supplemental New Drug Application for its oral, once-daily direct factor Xa-inhibitor LIXIANA® (Edoxaban Tosilate Hydrate) for review by the Japanese Ministry of Health, Labour and Welfare. Daiichi Sankyo is seeking approval in Japan for edoxaban in new indications for non-valvular atrial fibrillation and symptomatic venous thromboembolism. [More]
Daiichi Sankyo presents subgroup analysis of Hokusai-VTE study at ASH annual meeting

Daiichi Sankyo presents subgroup analysis of Hokusai-VTE study at ASH annual meeting

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced results of a prespecified subgroup analysis of 771 cancer patients enrolled in the phase 3 Hokusai-VTE study. [More]
Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics, Inc. today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013. [More]
Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD), at the 55th Annual Meeting of the American Society of Hematology (ASH) held December 7 - 10, 2013 in New Orleans. [More]
Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

People inherit different versions of any particular gene, and some genes affect how patients process and metabolize medicines. This especially holds true for people with cardiovascular (CV) disease. They may be fast, slow or non-metabolizers and might also react badly (with serious adverse events) to certain drug therapies or not at all. [More]
Natural compound coumarins exhibit anti-inflammatory as well as anticoagulant activities

Natural compound coumarins exhibit anti-inflammatory as well as anticoagulant activities

New methods for the laboratory-scale synthesis of coumarin-based drugs were developed in a recent study completed at the University of Eastern Finland. In his doctoral thesis, Lic. Phil. Juri Timonen also developed new analytical methods for the fast identification of natural and non-natural coumarins. [More]
Patients at highest risk for suffering full-blown ischemic attack less likely to receive optimal care

Patients at highest risk for suffering full-blown ischemic attack less likely to receive optimal care

Among thousands of hospital patients treated for a "mini stroke," those who were at highest risk for suffering a full-blown ischemic attack were less likely to received optimal care, according to a study led by researchers at Duke Medicine. [More]

Once-daily edoxaban prevents stroke in patients with atrial fibrillation

According to the United States Centers for Disease Control and Prevention, over 800,000 Americans die each year from heart disease and stroke. Stroke is the leading cause of serious long-term disability and death in the US. In addition to lifestyle changes, medications such as anti-blood clotting drugs are helpful in the prevention of stroke. [More]
Treating traumatic brain-injured patients with anticoagulant decreases risk of dangerous clots

Treating traumatic brain-injured patients with anticoagulant decreases risk of dangerous clots

Researchers from the University of Missouri School of Medicine have found that a new protocol that uses preventive blood-thinning medication in the treatment of patients with traumatic brain injuries reduces the risk of patients developing life-threatening blood clots without increasing the risk of bleeding inside the brain. [More]
New strategy for emergency anticoagulant treatment for patients with myocardial infarction

New strategy for emergency anticoagulant treatment for patients with myocardial infarction

A new strategy for emergency anticoagulant treatment for patients with acute myocardial infarction has been put in place by a team led by Philippe-Gabriel Steg at Inserm Unit 698 (Haemostasis, Bioengineering, Immunopathology and Cardiovascular Remodelling), at H-pital Bichat, AP-HP, Universit- Paris Diderot). [More]

New study guides clinicians and policy makers on cost-effectiveness of anticoagulant drugs

Patients who are responding below par to the anticoagulant drug warfarin have several options. They can undergo even more blood tests to monitor their response to the different dosages of this medication which is prescribed to prevent strokes, or they could start using one of the newer, yet more expensive, anticoagulants on the market. [More]
Scientists introduce new approach to the production of synthetic heparin mimetics

Scientists introduce new approach to the production of synthetic heparin mimetics

One of the risks of any large operation is the occurrence of blood clots. To prevent this, patients are routinely given the anticoagulant heparin or related drugs. American scientists have now introduced a new approach to the production of synthetic heparin mimetics with better activity profiles. [More]

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Janssen Pharmaceuticals, Inc. announced today a newly published, pooled analysis of the Phase III EINSTEIN trial program, showing XARELTO (rivaroxaban) is as effective as the standard of care in reducing the risk of deep vein thrombosis and pulmonary embolism in people with symptomatic DVT or PE, while reducing the incidence of major bleeding by 46 percent. [More]

Regado Biosciences announces enrollment of first patient in REGULATE-PCI clinical trial

Regado Biosciences, Inc., a biopharmaceutical company focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications, today announced the enrollment of the first patient in its REGULATE-PCI clinical trial. [More]